1998
Resultado da Busca
Hansa Biopharma är baserat i Lund och har verksamhet i Europa och USA. Bolaget är noterat på Nasdaq Stockholm under kortnamnet HNSA. Läs mer på www.hansabiopharma.com och följ oss på LinkedIn. ©2024 Hansa Biopharma. Hansa Biopharma, beacon-logotypen och IDEFIRIX är varumärken som tillhör Hansa Biopharma AB, Lund, Sverige.
Model Alec Ruygrok and photographer Trent Pace team up for our latest exclusive story. For the latest edition of MMSCENE PORTRAITS photographer Trent Pace captures model Alex Ruygrok from Chic Management. Talent – Alex Ruygrok at Chic Management @alexanderruygrok @chic_management. Photographer – Trent Pace @trentpacephoto.
Le Pen’s protégé, Jordan Bardella, will win the EU... The former British Somaliland gained its independe... How Tiny Djibouti Said ‘No’ to the US; Börsen 17 maj 2024; PIGS Are Flying Again. Huvudmannen i ekobrottshärvan i Malmfälten är spår... Kina tar krafttag nu när bostadspriserna snart fal... France Rushes Reinforcements to ...
Lund, Sweden, 31 May, 2024. Hansa Biopharma AB, ('Hansa' or the 'Company') (Nasdaq Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete.
No persons under the age of 18 are permitted to gamble. South African Responsible Gambling Foundation toll free counselling line 0800 006 008
LUND, Sweden, May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label, randomized, controlled trial of imlifidase in kidney transplantation.
Lund, Sweden, 31 May, 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label, randomized, controlled trial of imlifidase in kidney transplantation.
